Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Side effects of tuberculosis treatment with fixed-dose combinations Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Latent tuberculosis infection prevalence and risk of developing active TB among patients eligible for starting anti-TNFα therapy Source: International Congress 2015 – Screening strategies in TB Year: 2015
Impact of food intake on pharmacokinetics(PK) of first-line tuberculosis drugs in treatment-naive patients Source: International Congress 2014 – Mycobacterium tuberculosis infection: new therapeutic approaches Year: 2014
Advantages of intravenous chemotherapy for tuberculosis patients with viral hepatitis Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
The pharmacogenomics in the personalization of isoniazid treatment of patients with tuberculosis Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Safety of bedaquiline for treatment of MDR/XDR tuberculosis in HIV co-infected patients Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019
The effectiveness of TB treatment in patients with gastrointestinal tract disorders, depending on the way of administration of anti-TB drugs Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Outcomes of treatment of latent tuberculosis infection in children with two different regimens Source: Eur Respir J 2006; 28: Suppl. 50, 487s Year: 2006
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006
Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004
Treatment effectiveness of TB patients from different groups of population in Moscow Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013
Immuno-allergic reactions to antituberculosis treatment Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management II Year: 2013